Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). METHODS: Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end point was the percentage of overall responders (patients reporting ≥30% reduction from baseline in worst abdominal pain plus an increase of ≥1 complete spontaneous bowel movement (CSBM)/week from baseline in the same week for ≥6 of 12 treatment weeks). Safety was assessed by adverse events (AEs). RESULTS: Overall, 2189 individuals were randomized across the two studies and 1879 completed the studies. Demographic and baseline characteristics were similar across treatment groups and between studies. The percentage of overall responders in Study 1 was 30.2% and 29.5% for plecanatide 3 and 6 mg, respectively, vs. 17.8% placebo (P < 0.001 for each dose vs. placebo), and in Study 2 was 21.5% (P = 0.009) and 24.0% (P < 0.001) for plecanatide 3 and 6 mg, respectively, compared to 14.2% for placebo. The percentage of sustained efficacy responders (overall responders plus weekly responders for ≥2 of last 4 weeks of the 12-week treatment period) was significantly greater for both doses of plecanatide vs. placebo across both studies. All secondary end points (stool frequency/consistency, straining, abdominal symptoms) showed statistically significant improvements compared with placebo. The most common AE was diarrhea (3 mg, 4.3%; 6 mg, 4.0%; placebo, 1.0%). Discontinuation due to diarrhea was infrequent (3 mg, 1.2%; 6 mg, 1.4%; placebo, 0). CONCLUSIONS: Plecanatide significantly improved both abdominal pain and constipation symptoms of IBS-C with minimal associated side effects and high levels of tolerability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Plecanatide may have beneficial concurrent effects with relief in abdominal pain based on indirect evidence from IBS-C trials. 74”
In the citing paper
“Placebo-controlled trials have demonstrated efficacy of these drugs in IBS-C”
From Irritable bowel syndrome (2020) · cites this paper as [117]
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Intestinal barrier function in health and gastrointestinal disease
Camilleri, M., Madsen, K., Spiller, R., Van Meerveld, B. G., & Verne, G. N. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01921.x · Cited by 908
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494
Bertiaux-Vandaële, N., Youmba, S. B., Belmonte, L., Lecleire, S., Antonietti, M., Gourcerol, G., Leroi, A.-M., Déchelotte, P., Ménard, J.-F., Ducrotté, P., et al. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.257 · Cited by 294
Busby, R. W., Bryant, A. P., Bartolini, W. P., Cordero, E. A., Hannig, G., Kessler, M. M., Mahajan-Miklos, S., Pierce, C. M., Solinga, R. M., Sun, L. J., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.019 · Cited by 235
Drossman, D. A., Morris, C. B., Schneck, S., Hu, Y. J. B., Norton, N. J., Norton, W. F., Weinland, S. R., Dalton, C., Leserman, J., & Bangdiwala, S. I. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318189a7f9 · Cited by 235
Vaandrager, A. B., Smolenski, A., Tilly, B. C., Houtsmuller, A. B., Ehlert, E. M. E., Bot, A. G. M., Edixhoven, M., Boomaars, W. E. M., Lohmann, S. M., & de Jonge, H. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1466 · Cited by 174
Heidelbaugh, J. J., Stelwagon, M., Miller, S. A., Shea, E. P., & Chey, W. D. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.67 · Cited by 157
Research works printed but not linked: 2
- Doshi, 2014, J Manag Care Spec Pharm, 20, 382
- Tse, 2017, J Gastroenterol Hepatol, 2017, 8612189
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
“The safety and efficacy of plecanatide has been evaluated in 3 individual phase IIb/III studies (180,181) and 1 subsequent systematic review/meta-analysis (173).”
BackgroundSelf-citationFord, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31548-8 · Cited by 818
An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation
Aziz, I., Whitehead, W. E., Palsson, O. S., Törnblom, H., & Simrén, M. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1708718 · Cited by 413
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
“Three RCTs were identified, two phase 3 RCTs published in press in a single article [249], and one doseranging trial published in abstract form only [250], containing”
BackgroundMethodDiagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Metadata
- Authors
- Brenner, D. M., Fogel, R., Dorn, S. D., Krause, R., Eng, P., Kirshoff, R., Nguyen, A., Crozier, R. A., Magnus, L., & Griffin, P. H.
- Affiliations
- Northwestern University (US)
- Venue
- American Journal of Gastroenterology
- Published
- 2018-05
- Volume
- 113
- Issue
- 5
- Pages
- 735-745
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2792615508
- Cited by
- 145
- References
- 32
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 31 · 2020: 27 · 2019: 6 · 2018: 14
- FWCI
- 18.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Allergan
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- plecanatide, irritable bowel syndrome with constipation, guanylate cyclase-C agonist, abdominal pain, constipation, spontaneous bowel movements, stool frequency, straining, diarrhea, drug safety and tolerability
- MeSH terms
- Adult, Aged, Aged, 80 and over, Constipation, Defecation, Diarrhea, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Placebos, Abdominal Pain, Treatment Outcome, Irritable Bowel Syndrome, Natriuretic Peptides, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. https://app.cochat.ai/papers/10.1038/s41395-018-0026-7
- The paper
- Brenner, D. M., Fogel, R., Dorn, S. D., Krause, R., Eng, P., Kirshoff, R., Nguyen, A., Crozier, R. A., Magnus, L., & Griffin, P. H. (2018). Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. American Journal of Gastroenterology. https://doi.org/10.1038/s41395-018-0026-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.